NAMS
NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Co N.V. (NAMS) has 3 SEC Form 4 filings (12 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jul 22, 2026.
The most active filer is Chief Accounting Officer Kooij Louise Frederika with 3 filings. Insiders have net sold $6.7M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Michael Davidson
- Employees:100
- HQ:Naarden, NH, NL
- IPO:2021-02-09
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$6.7M
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Market Cap
$3.7B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Accounting Officer | Sale | 105,000 | $3.2M | Jul 22 | SEC ↗ | |
| Chief Accounting Officer | Sale | 40,000 | $1.2M | Jun 24 | SEC ↗ | |
Kooij Louise FrederikaFirst filing | Chief Accounting Officer | Sale | 65,000 | $2.3M | May 27 | SEC ↗ |
Related companies
NewAmsterdam Pharma Co N.V. is in the Healthcare sector.